Butantan firma acordo para desenvolver terapia inovadora contra l�pus e miastenia

The Butantan Institute is set to announce a significant collaboration with the Hemocentro de Ribeirão Preto, USP, and Fapesp to develop cutting-edge therapies for autoimmune diseases like systemic lupus erythematosus and generalized myasthenia gravis. This partnership aims to advance medical science and provide much-needed treatment options for those suffering from these debilitating conditions. The agreement highlights the importance of public-private partnerships in advancing healthcare and underscores Brazil's commitment to tackling complex medical challenges.